• Personalized treatment of hepatitis C genotype 1a in Norway and Sweden 2014-2016: a study of treatment outcome in patients with or without resistance-based DAA-therapy 

      Kileng, Hege; Kjellin, Midori; Akaberi, Dario; Bergfors, Assar; Duberg, Ann-Sofi; Wesslen, Lars; Danielsson, Astrid; Kristiansen, Magnhild Gangsøy; Gutteberg, Tore Jarl; Goll, Rasmus; Lannergård, Anders; Lennerstrand, Johan (Journal article; Tidsskriftartikkel; Peer reviewed, 2018-11-05)
      <i>Objectives</i>: Resistance-associated substitutions (RASs) may impair treatment response to direct-acting antivirals (DAA) in hepatitis C virus (HCV) treatment. We investigated the effects of baseline NS3-RASs (Q80K and R155K) and clinically relevant NS5A-RASs in patients with HCV genotype (GT) 1a infection on treatment outcome, with or without resistance-based DAA-treatment. This multi-center ...